Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) EBITDA (2016 - 2025)

Myriad Genetics (MYGN) has disclosed EBITDA for 17 consecutive years, with -$5.7 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 85.38% to -$5.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$387.2 million through Dec 2025, down 213.78% year-over-year, with the annual reading at -$387.2 million for FY2025, 213.52% down from the prior year.
  • EBITDA for Q4 2025 was -$5.7 million at Myriad Genetics, up from -$23.3 million in the prior quarter.
  • The five-year high for EBITDA was -$5.7 million in Q4 2025, with the low at -$329.2 million in Q2 2025.
  • Average EBITDA over 5 years is -$55.0 million, with a median of -$37.8 million recorded in 2024.
  • Peak annual rise in EBITDA hit 85.38% in 2025, while the deepest fall reached 801.92% in 2025.
  • Over 5 years, EBITDA stood at -$43.1 million in 2021, then fell by 21.11% to -$52.2 million in 2022, then skyrocketed by 39.85% to -$31.4 million in 2023, then fell by 24.2% to -$39.0 million in 2024, then surged by 85.38% to -$5.7 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$5.7 million, -$23.3 million, and -$329.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.